Article Text

Download PDFPDF

P09.09 PD-1 checkpoint blockade for treatment of mucormycosis and invasive aspergillosis in a stem cell transplant recipient
  1. N Mueller1,2,
  2. J Banck1,
  3. S Mellinghoff3,
  4. H Schlösser4,5,
  5. M Thelen4,5,
  6. P Koehler3,
  7. F Schrötzlmair6,
  8. O Cornely3,
  9. LH Lindner1 and
  10. M von Bergwelt-Baildon1,7,8
  1. 1Department of Medicine III, University Hospital, LMU Munich, Munich, Germany
  2. 2Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany
  3. 3University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Excellence Center for Medical Mycology (ECMM), Cologne, Germany
  4. 4Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
  5. 5Department of General, Visceral, Cancer and Transplantation Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
  6. 6Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, LMU Munich, Munich, Germany
  7. 7German Cancer Consortium (DKTK), partner site Munich, Munich, Germany
  8. 8Work group iCHOP (Intensive Care in Hematologic and Oncologic Patients), Berlin, Germany


Background Despite early surgical debridement and application of systemic antifungal drugs, invasive fungal infections by mucor spp. are still associated with a very poor prognosis in immunocompromised patients. Due to their lack of immune defense, targeted treatment strategies reversing the hyporesponsiveness of the immune system by immune checkpoints might improve patients’ outcome. Until today, a successful recovery of mucormycosis after receiving anti-PD-1 antibody is only described once for a polytrauma patient. Therefore, we here describe the first immunosuppressed patient treated with nivolumab for invasive mucormycosis with aspergillus coinfection.

Materials and Methods A 51-year-old woman from Germany with acute myeloid leukemia (AML) relapse after allogenic hematopoietic stem cell transplantation was treated with azacitidine and lenalidomide. She acquired an invasive fungal infection with mucor species Lichtheimia ramosa combined with Aspergillus fumigatus in functional pancytopenia. Three surgical pansinusrevisions were performed and high dose i.v. antifungal treatment with liposomal amphotericin B and isavuconazole was initiated. Due to missing treatment response with daily mucor progression nivolumab 240 mg was administered and complemented by interferon γ (100µg s.c. 5 doses). Administration was repeated every 2 weeks (in total 4 doses of nivolumab, but only 10 doses of interferon γ due to recurrent fever episodes) and simultaneously i.v. antifungal treatment was deescalated. Blood samples were collected before (baseline treatment (BT)) as well as 2 weeks (under treatment (UT) 1) and 5 weeks (UT2) after treatment initiation with nivolumab. Peripheral blood mononuclear cells were isolated and flow cytometry analyses of lymphocytic subsets were performed.

Results Ten days after first dose of nivolumab, long-term local hemostasis was achieved. Local symptoms disappeared, sinusitis complaints improved, and inflammation values decreased significantly. Sixteen days after treatment initiation a CT scan revealed a partial remission of mucormycosis invasion. Follow-up CT scans showed a stable disease. Expression of PD-1 on T cells was monitored as proof of concept from BT on and showed a significant reduction from 34.7% to 3.3% (UT1) and 1.38% (UT2). Both activation markers CD86 and CD69 showed an increase from BT to UT1. T cells showed high maturation markers throughout monitoring, while B cell maturation increased from BT to UT1/2. Nine weeks after diagnosis and despite long-term neutropenia the patient was still clinically stable under nivolumab treatment and discharged with continued deescalated antimycotic treatment. A bone marrow biopsy revealed a further progression of AML relapse. After 3 weeks during follow-up mucormycosis was still clinically stable. Ten days later the patient developed fever up to 39.5°C, but refused to seek medical attention due to unfavorable prognosis of AML and died two days later from septic shock combined with disseminated intravascular coagulation.

Conclusions In immunocompromised hematological patients with invasive fungal infections, immune checkpoint inhibition is capable of reversing an infection-induced immunosuppressive phenotype. Therefore, it might complement the treatment of invasive fungal infections and should be evaluated in future clinical trials.

Disclosure Information N. Mueller: None. J. Banck: None. S. Mellinghoff: None. H. Schlösser: None. M. Thelen: None. P. Koehler: None. F. Schrötzlmair: None. O. Cornely: None. L.H. Lindner: None. M. von Bergwelt-Baildon: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.